1Bolger AP, Anker SD. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestaion and therapeutic implications[J].Drugs,2000, 60(6): 1245 - 1257. 被引量：1
2Torre-amione G, Vooletich MT, FarmerJA. Role of tumour necrosis factor-alpha in the progression of heart failure:therapeutic implications[ J ]. Drugs, 2000, 59 (4): 745 -751. 被引量：1
3Sack M. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factoralpha therapy in heart disease[J]. Pharmacol Ther, 2002,94(1/2): 123 - 135. 被引量：1
4Lisman KA, Stetson SJ, Koerner MM, et al. The role of tumor necrosis factor-alpha blockade in the treatment of congestive heart failure[J]. Congest Heart Fail, 2002, 8(5):275 - 279. 被引量：1
5Bradham WS, Bozkurt B, Gunasinghe H, et al. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective[ J]. Cardiovasc Res, 2002, 53(4):822-830. 被引量：1
6Levine B, Kalman J, Mayer L, et al. Elevated circulation levels of tumor necrosis factor in severe chronic heart failure[J]. N Engl J Med, 1990, 323(4):236-241. 被引量：1
7Meurs KM, Fox PR, Miller MW, et al. Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure[J]. Am J Vet Res, 2002, 63(5) :640- 642. 被引量：1
8Gunasinghe HR, Coker ML, Trop AJ, et al, Increased matrix metalloproteinases plasma levels in patients with congestive heart failure:relation to cytokine activation[J]. Circulation, 2000, 102: Ⅱ 403. 被引量：1
9Bradham WS, Moe G, Wendt KA, et al. TNF-α and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling[J]. Am JPhysiol Heart Circ Physiol, 2002, 282(4): H1288 - H1295. 被引量：1
10Sliwa K,Skudicky D, Candy G, et al. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy [ J ]. Lancet,1998, 351(909): 1091 - 1093. 被引量：1
